消化管間質腫瘍:治療薬開発パイプライン動向(2016年下半期版)

Global Markets Directが発行した調査報告書(DATA70209271)
◆英語タイトル:Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2016
◆商品コード:DATA70209271
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2016年11月16日
◆ページ数:210
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
Site LicenseUSD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Enterprisewide (Global Site License)USD6,000 ⇒換算¥678,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、世界における消化管間質腫瘍の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。
・イントロダクション
・消化管間質腫瘍の概要
・消化管間質腫瘍治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・消化管間質腫瘍パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・企業別、開発中の製品
・大学/研究機関別、研究中の製品
・消化管間質腫瘍治療薬開発に取り組んでいる企業:企業別製品パイプライン
・消化管間質腫瘍治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Gastrointestinal Stromal Tumor (GIST) – Pipeline Review, H2 2016

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Gastrointestinal Stromal Tumor – Pipeline Review, H2 2016, provides an overview of the Gastrointestinal Stromal Tumor (Oncology) pipeline landscape.

Gastrointestinal stromal tumors (GISTs) are tumors, which occur in the gastrointestinal tract. Gastrointestinal stromal tumors belong to a group of cancers called soft tissue sarcoma. GISTs can be benign or malignant tumors. The symptoms of GIST include pain or discomfort in the abdomen, a mass in the abdomen that can feel with the hand, nausea and vomiting, vomiting blood or having blood in the stool and fatigue due to anemia (low red blood cell counts). Gastrointestinal stromal tumor treatment involves the use of surgery, radiation therapy, targeted therapy and chemotherapy.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Gastrointestinal Stromal Tumor – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Gastrointestinal Stromal Tumor (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastrointestinal Stromal Tumor (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastrointestinal Stromal Tumor (GIST) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 15, 10, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.Gastrointestinal Stromal Tumor.

Gastrointestinal Stromal Tumor (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Gastrointestinal Stromal Tumor (Oncology).
- The pipeline guide reviews pipeline therapeutics for Gastrointestinal Stromal Tumor (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Gastrointestinal Stromal Tumor (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Gastrointestinal Stromal Tumor (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Gastrointestinal Stromal Tumor (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Gastrointestinal Stromal Tumor (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Gastrointestinal Stromal Tumor (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Gastrointestinal Stromal Tumor (GIST) Overview 10
Therapeutics Development 11
Pipeline Products for Gastrointestinal Stromal Tumor (GIST) – Overview 11
Pipeline Products for Gastrointestinal Stromal Tumor (GIST) – Comparative Analysis 12
Gastrointestinal Stromal Tumor (GIST) – Therapeutics under Development by Companies 13
Gastrointestinal Stromal Tumor (GIST) – Therapeutics under Investigation by Universities/Institutes 15
Gastrointestinal Stromal Tumor (GIST) – Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Gastrointestinal Stromal Tumor (GIST) – Products under Development by Companies 19
Gastrointestinal Stromal Tumor (GIST) – Products under Investigation by Universities/Institutes 21
Gastrointestinal Stromal Tumor (GIST) – Companies Involved in Therapeutics Development 22
AB Science SA 22
Advanced Accelerator Applications S.A. 23
Advenchen Laboratories, LLC 24
Ariad Pharmaceuticals, Inc. 25
Arog Pharmaceuticals, Inc. 26
ArQule, Inc. 27
Array BioPharma Inc. 28
Astex Pharmaceuticals Inc 29
Blueprint Medicines Corporation 30
Boston Biomedical, Inc. 31
Calithera Biosciences, Inc. 32
Chipscreen Biosciences Ltd 33
Daiichi Sankyo Company, Limited 34
Deciphera Pharmaceuticals, LLC 35
F. Hoffmann-La Roche Ltd. 36
Horizon Pharma Plc 37
Immunicum AB 38
Jiangsu Hengrui Medicine Co., Ltd. 39
Kolltan Pharmaceuticals, Inc. 40
Natco Pharma Limited 41
Nerviano Medical Sciences S.r.l. 42
Novartis AG 43
Omeros Corporation 44
Plexxikon Inc. 45
Rhizen Pharmaceuticals S.A. 46
Taiho Pharmaceutical Co., Ltd. 47
Gastrointestinal Stromal Tumor (GIST) – Therapeutics Assessment 48
Assessment by Monotherapy Products 48
Assessment by Combination Products 49
Assessment by Target 50
Assessment by Mechanism of Action 53
Assessment by Route of Administration 57
Assessment by Molecule Type 59
Drug Profiles 61
alpelisib – Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
amcasertib – Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
apatinib – Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
ARQ-092 – Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
binimetinib – Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
BLU-285 – Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
buparlisib hydrochloride – Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
CB-839 – Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
CHMFLKIT-110 – Drug Profile 93
Product Description 93
Mechanism Of Action 93
R&D Progress 93
crenolanib besylate – Drug Profile 94
Product Description 94
Mechanism Of Action 94
R&D Progress 94
CS-2164 – Drug Profile 97
Product Description 97
Mechanism Of Action 97
R&D Progress 97
dabrafenib mesylate + trametinib dimethyl sulfoxide – Drug Profile 98
Product Description 98
Mechanism Of Action 98
R&D Progress 98
DCC-2618 – Drug Profile 105
Product Description 105
Mechanism Of Action 105
R&D Progress 105
everolimus – Drug Profile 106
Product Description 106
Mechanism Of Action 106
R&D Progress 106
infigratinib – Drug Profile 117
Product Description 117
Mechanism Of Action 117
R&D Progress 117
interferon gamma-1b – Drug Profile 119
Product Description 119
Mechanism Of Action 119
R&D Progress 119
Intuvax – Drug Profile 123
Product Description 123
Mechanism Of Action 123
R&D Progress 123
KTN-0158 – Drug Profile 129
Product Description 129
Mechanism Of Action 129
R&D Progress 129
masitinib – Drug Profile 131
Product Description 131
Mechanism Of Action 131
R&D Progress 131
nilotinib – Drug Profile 144
Product Description 144
Mechanism Of Action 144
R&D Progress 144
NMSP-088 – Drug Profile 149
Product Description 149
Mechanism Of Action 149
R&D Progress 149
NRCAN-019 – Drug Profile 150
Product Description 150
Mechanism Of Action 150
R&D Progress 150
onalespib – Drug Profile 152
Product Description 152
Mechanism Of Action 152
R&D Progress 152
Peptide to Antagonize GRPR for Oncology – Drug Profile 156
Product Description 156
Mechanism Of Action 156
R&D Progress 156
pexidartinib – Drug Profile 157
Product Description 157
Mechanism Of Action 157
R&D Progress 157
PLX-9486 – Drug Profile 161
Product Description 161
Mechanism Of Action 161
R&D Progress 161
ponatinib hydrochloride – Drug Profile 162
Product Description 162
Mechanism Of Action 162
R&D Progress 162
SF-1126 – Drug Profile 175
Product Description 175
Mechanism Of Action 175
R&D Progress 175
SHR-1020 – Drug Profile 177
Product Description 177
Mechanism Of Action 177
R&D Progress 177
Small Molecule to Antagonize GPR20 for Acute Myeloid Leukemia and Gastro-Intestinal Stromal Tumors – Drug Profile 179
Product Description 179
Mechanism Of Action 179
R&D Progress 179
Small Molecules to Inhibit c-Kit for Gastrointestinal Stromal Tumor – Drug Profile 180
Product Description 180
Mechanism Of Action 180
R&D Progress 180
TAS-116 – Drug Profile 181
Product Description 181
Mechanism Of Action 181
R&D Progress 181
TGR-1202 – Drug Profile 182
Product Description 182
Mechanism Of Action 182
R&D Progress 182
vemurafenib – Drug Profile 189
Product Description 189
Mechanism Of Action 189
R&D Progress 189
Gastrointestinal Stromal Tumor (GIST) – Dormant Projects 196
Gastrointestinal Stromal Tumor (GIST) – Discontinued Products 197
Gastrointestinal Stromal Tumor (GIST) – Product Development Milestones 198
Featured News & Press Releases 198
Oct 31, 2016: Deciphera Pharmaceuticals to Present Clinical Data on DCC-2618 at 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 198
Jul 13, 2016: Boston Biomedical Announces Generic Name of BBI-503: Amcasertib 198
May 24, 2016: Arog Pharmaceuticals Presents Crenolanib Clinical Data at the 2016 American Society of Clinical Oncology Annual Meeting 199
Apr 20, 2016: Kolltan Pharmaceuticals Announces Presentations of Anti-KIT Antibody Preclinical Data at the 2016 American Association for Cancer Research Annual Meeting 200
Jul 13, 2015: Blueprint Medicines Receives FDA Authorization to Proceed with Clinical Trials for BLU-285 201
Apr 19, 2015: Blueprint Medicines Presents New Preclinical Data Demonstrating Significant Anti-Tumor Activity of BLU-285 in Treatment-Resistant GIST and on Novel Cancer Drug Targets 201
Apr 08, 2015: Blueprint Medicines to Present New Preclinical Data on BLU-285 in Treatment-Resistant GIST and on Novel Cancer Drug Targets at Upcoming AACR Annual Meeting 202
Jun 01, 2014: ARIAD Announces Initial Data from Phase 2 Trial of Ponatinib in Patients with Gastrointestinal Stromal Tumors 202
Mar 20, 2014: CHMP Adopts Negative Opinion For AB Science’s Masican 203
Oct 09, 2013: ARIAD Announces Changes in the Clinical Development Program of Iclusig 204
Jun 11, 2013: Ariad Pharma Initiates Phase II Trial Of Ponatinib In Patients With Gastrointestinal Stromal Tumors 205
Apr 09, 2013: Ariad Pharma Presents New Preclinical Data Showing Ponatinib Overcomes Resistant Mutations In Oncogenic Driver Of Gastrointestinal Stromal Tumors 206
Mar 20, 2013: Ariad Pharma Announces Presentations Of Preclinical Data On Iclusig At AACR Annual Meeting 206
Oct 04, 2012: AB Science Announces Acceptance Of Marketing Application For Masitinib By EMA To Treat Gleevec-resistant Gastro-intestinal Stromal Tumor 207
Feb 01, 2012: AB Science Reports Encouraging Results From Phase II Study With Its Investigational Drug, Masitinib 207
Appendix 209
Methodology 209
Coverage 209
Secondary Research 209
Primary Research 209
Expert Panel Validation 209
Contact Us 209
Disclaimer 210

List of Tables
Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H2 2016 11
Number of Products under Development for Gastrointestinal Stromal Tumor (GIST) - Comparative Analysis, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Number of Products under Development by Companies, H2 2016 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Comparative Analysis by Late Stage Development, H2 2016 16
Comparative Analysis by Clinical Stage Development, H2 2016 17
Comparative Analysis by Early Stage Development, H2 2016 18
Products under Development by Companies, H2 2016 19
Products under Development by Companies, H2 2016 (Contd..1) 20
Products under Investigation by Universities/Institutes, H2 2016 21
Gastrointestinal Stromal Tumor (GIST) - Pipeline by AB Science SA, H2 2016 22
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Advanced Accelerator Applications S.A., H2 2016 23
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Advenchen Laboratories, LLC, H2 2016 24
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Ariad Pharmaceuticals, Inc., H2 2016 25
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Arog Pharmaceuticals, Inc., H2 2016 26
Gastrointestinal Stromal Tumor (GIST) - Pipeline by ArQule, Inc., H2 2016 27
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Array BioPharma Inc., H2 2016 28
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Astex Pharmaceuticals Inc, H2 2016 29
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Blueprint Medicines Corporation, H2 2016 30
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Boston Biomedical, Inc., H2 2016 31
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Calithera Biosciences, Inc., H2 2016 32
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Chipscreen Biosciences Ltd, H2 2016 33
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 34
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Deciphera Pharmaceuticals, LLC, H2 2016 35
Gastrointestinal Stromal Tumor (GIST) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 36
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Horizon Pharma Plc, H2 2016 37
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Immunicum AB, H2 2016 38
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016 39
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Kolltan Pharmaceuticals, Inc., H2 2016 40
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Natco Pharma Limited, H2 2016 41
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Nerviano Medical Sciences S.r.l., H2 2016 42
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Novartis AG, H2 2016 43
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Omeros Corporation, H2 2016 44
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Plexxikon Inc., H2 2016 45
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Rhizen Pharmaceuticals S.A., H2 2016 46
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2016 47
Assessment by Monotherapy Products, H2 2016 48
Assessment by Combination Products, H2 2016 49
Number of Products by Stage and Target, H2 2016 51
Number of Products by Stage and Mechanism of Action, H2 2016 54
Number of Products by Stage and Route of Administration, H2 2016 58
Number of Products by Stage and Molecule Type, H2 2016 60
Gastrointestinal Stromal Tumor (GIST) - Dormant Projects, H2 2016 196
Gastrointestinal Stromal Tumor (GIST) - Discontinued Products, H2 2016 197

List of Figures
Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H2 2016 11
Number of Products under Development for Gastrointestinal Stromal Tumor (GIST) - Comparative Analysis, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Comparative Analysis by Late Stage Development, H2 2016 16
Comparative Analysis by Clinical Stage Development, H2 2016 17
Comparative Analysis by Early Stage Products, H2 2016 18
Assessment by Monotherapy Products, H2 2016 48
Number of Products by Top 10 Targets, H2 2016 50
Number of Products by Stage and Top 10 Targets, H2 2016 50
Number of Products by Top 10 Mechanism of Actions, H2 2016 53
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 53
Number of Products by Routes of Administration, H2 2016 57
Number of Products by Stage and Routes of Administration, H2 2016 57
Number of Products by Molecule Types, H2 2016 59
Number of Products by Stage and Molecule Types, H2 2016 59

【レポートのキーワード】

消化管間質腫瘍

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 消化管間質腫瘍:治療薬開発パイプライン動向(2016年下半期版)(Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2016)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆